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Abstract
Background: The incidence and prevalence of CNS involvement in SLE remains unclear owing to conflicting results in the
published studies. The aim of the study was to evaluate the incidence and prevalence of major definite CNS events in SLE
patients.
Methods: 370 SLE patients with no previous history of CNS involvement were prospectively evaluated in a tertiary hospital
referral center for 3 years. Major CNS manifestations were codified according to ACR definitions, including chorea, aseptic
meningitis, psychosis, seizures, myelopathy, demyelinating syndrome, acute confusional state and strokes. Minor CNS
events were excluded. ECLAM and SLEDAI-SELENA Modification scores were used to evaluate disease activity and SLICC/
ACR Damage Index was used to assess accumulated damage.
Results: 16/370 (4.3%) patients presented with a total of 23 major CNS events. These included seizures (35%), strokes (26%),
myelopathy (22%), optic neuritis (8.7%), aseptic meningitis (4.3%) and acute psychosis (4.3%). Incidence was 7.8/100 person
years. Among hospitalizations for SLE, 13% were due to CNS manifestations. Epileptic seizures were associated with high
disease activity, while myelopathy correlated with lower disease activity and NMO-IgG antibodies (P#0.05). Stroke incidence
correlated with APS coexistence (P = 0.06). Overall, CNS involvement correlated with high ECLAM and SLEDAI scores
(P,0.001).
Conclusions: Clinically severe CNS involvement is rare in SLE patients, accounting for 7.8/100 person years. CNS
involvement correlates with high disease activity and coexistence of specific features that define the respective CNS
syndromes.
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Introduction
Systemic Lupus Erythematosus (SLE) is an autoimmune
systemic disease which has a prevalence of 52.2/100.000 in
the United States [1]. Neurological involvement in the
morbidity and mortality of SLE is considered significant [2–4]
and many studies have tried to determine the incidence and
prevalence of neurologic manifestations. Major obstacles have
been the often non-specific nature of these manifestations and
the scarcity of specific laboratory tests. In addition, the need to
differentiate Central Nervous System (CNS) involvement attrib-
uted to SLE from existing co-morbidities, drug adverse reactions
or infections [5,6] had generated further diagnostic dilemmas
[7]. In 1999, the American College of Rheumatology (ACR)
formulated a nomenclature system which provided case
definitions for 19 neuropsychiatric SLE syndromes[8].
Despite these advances, the reported frequency of neurologic
involvement in SLE continues to vary greatly, ranging from 12%
to 95% [9–12]. This discrepancy can be attributed to factors such
as study design, diagnostic approach and patients’ baseline
characteristics [10,12]. Still, the main reason has been the
inclusion of non-specific, minor symptoms including headaches,
mild cognitive dysfunction and depression, which may occur in
several chronic autoimmune diseases, treated with steroids and
immunosuppressants [3,13,14].
The aim of the present study was to evaluate the prevalence,
annual incidence and the clinical factors associated with definite
organic CNS manifestations, in a cohort of SLE patients.
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Materials and Methods
Study’s Sample
The study was conducted between July 1st 2008 and July 31st
2011 in the Department of Pathophysiology, University of Athens.
370 SLE patients (32614 years, 88% females) with no history of
CNS involvement attributed to SLE were consecutively included.
All patients fulfilled the 1997 ACR classification criteria for SLE
[15] and diagnosis was upon recognition of $4 ACR criteria.
Patients were informed about the scope and procedures of the
study and provided written informed consent. The study was
approved by the Scientific Council of ‘‘Laikon’’ University
Hospital and by the Ethical Committee of the Medical School.
Definition of the Organic CNS Involvement
Among the 19 ACR case definitions [8], we selected 8 objective
major CNS manifestations. These were chorea, aseptic meningitis,
psychosis, seizures, myelopathy, demyelinating syndrome, acute
confusional state and strokes. Diagnosis was based on neurological
examination, laboratory and imaging studies, and the exclusions
and associations proposed in the ACR glossary [8]. CNS
manifestations occurring in patients with recent cancer diagnosis
(,5 years), non-controlled hypo- or hyperthyroidism, active CNS
or systemic infection, HBV or HCV infection, and in patients who
had received medications with potential neurological adverse
reactions prior to the onset of the CNS manifestations, were
excluded.
All cases of Peripheral Nervous System (PNS) involvement were
excluded. Anxiety, headaches, subclinical cognitive dysfunction
and mild depression were also excluded, as they lack SLE
specificity [3,13,16]. Subclinical cognitive dysfunction is not an
uncommon finding among SLE patients with or without overt
CNS manifestations [17,18] and also appears in the Antiphos-
pholipid Syndrome (APS) [19]. Searching for non self-reported
cognitive deficits was beyond the scope of our study. Therefore, no
detailed neuropsychological battery was applied. The Mini Mental
Scale Examination (MMSE) [20,21] was performed in all patients
with self-reported cognitive deficits during neurological examina-
tion, and overt cognitive dysfunction was defined as a MMSE
score of ,25.
Clinical and Laboratory Assessment
All major CNS manifestations attributed to SLE that
occurred during the study period were recorded. Upon first
visit, patients gave a medical history and underwent clinical and
neurological examination, including routine laboratory and
immunological testing. Demographic data were recorded.
European Consensus Lupus Activity Measurement score
(ECLAM) [22] and Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) - SELENA Modification [23], were
used to evaluate disease activity. The SLICC/ACR Damage
Index (SDI) [24] was used to assess accumulated damage due to
the disease. As ECLAM, SLEDAI and SDI scores include
neurological variables they were also calculated after removing
these variables. The indexes without neurological variables are
referred to as modified ECLAM, SLEDAI and SDI (m-
ECLAM, m-SLEDAI and m-SDI, respectively). The types of
glomerulonephritis were classified according to the 2003
International Society of Nephrology/Renal Pathology Society
(ISN/RPS) classification [25]. Secondary APS was diagnosed
according to the 2006 update of the 1999 ACR criteria [26].
Patients were evaluated every 4 to 8 months or every time a
disease relapse or complication occurred. Hospitalizations,
irrespective of the overriding symptom, were recorded. A
clinical and neurological examination by the same expert
neurologist and CSF examinations/Magnetic Resonance Imag-
ing (MRI)/Electroencephalogram (EEG) were conducted when-
ever a CNS event occurred. The presence of Antinuclear
Antibodies (ANA) and anti-Ribosomal P antibodies [27] was
detected by Indirect Immunofluorescence (IIF) on Hep-2 cells,
while NMO-IgG/anti-AQP4 antibodies were detected by IIF on
mouse brain tissue and a cell based assay [28,29]. ECLAM,
SLEDAI and SDI scores were calculated at the occurrence of
every new CNS event.
Statistical Analysis
Continuous variables are presented as mean 6 SD when
normally distributed, or as median and quartiles when skewed.
Categorical variables are presented as frequencies. Normality was
graphically tested using P-P plots. The chi-square test (categorical
variables) and the Mann-Whitney test (quantitative variables) were
used to evaluate associations between subgroups of patients with
CNS involvement. Incidence was evaluated among newly
diagnosed SLE patients using the person years of observation.
Binary logistic regression models were applied to evaluate
associations of patients’ characteristics with CNS involvement.
Results are presented as odds ratios and the corresponding 95%
confidence intervals. Hosmer-Lemeshow statistics were used to
evaluate all models’ goodness of fit. The level of statistical
significance was P#0.05. SPSS statistical software was used for
analyses (SPSS Hellas Inc., Athens, Greece).
Results
Prevalence and Incidence
A total of 370 SLE patients with no prior CNS manifesta-
tions were enrolled. Patients were predominantly female (88%),
with a mean age of 32614 and mean disease duration of 967.8
years. Demographic and clinical characteristics are presented in
Table 1. After excluding the non-specific minor CNS complaints
(n = 76 patients), the prevalence of major CNS events among
SLE patients was 4.3%; 16/370 patients presented a total of 23
CNS events. The 23 CNS events were: seizures (n = 8, 35%),
strokes (n = 6, 26%), myelopathy (n= 5, 22%), optic neuritis
(n = 2, 8.7%), aseptic meningitis (n = 1, 4.3%) and acute
psychosis (n = 1, 4.3%). All seizures were generalized tonic–
clonic, while 3 patients evolved to status epilepticus. All strokes
were ischemic. Two patients had 2 or more, small ischemic
lesions, 2 patients had a large infarct due to thrombosis of a
central artery, while one patient manifested multiple transient
ischemic attacks in the course of days. Optic neuritis presented
as part of Neuromyelitis Optica. Chorea, acute demyelinating
disease and acute confusional state were not observed during
the 3-year observation period. Finally, no patients were defined
as having overt cognitive deficits (MMSE ,25).
Seven out of 16 patients had CNS involvement upon diagnosis
(44%), while 4 patients (25%) had a relapse of their initial CNS
manifestations within the 3-year period. Two out of 16 patients
(13%) had concurrent CNS manifestations; one presented with
myelitis and optic neuritis, and the other with aseptic meningitis
and psychosis. No death occurred in patients with CNS
involvement. The all-cause mortality rate of the entire cohort
(n=370) during the follow up period was 0.5%. Demographic and
clinical characteristics of SLE patients with CNS involvement are
presented in Table 1.
Finally, the annual incidence of major CNS events among
newly diagnosed SLE patients was 7.8 events/100 person-years
(i.e., 8 cases out of 55 SLE patients).
Major Central Nervous System Involvement in SLE
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Table 1. Demographic and clinical characteristics of the SLE patients.
Patient Characteristics All SLE patients (n=370)
Patients with CNS Involvement
(n =16)
Age at diagnosis (m 6 SD) 32614 30612
Sex
Male, n (%) 43 (12%) 1 (6.3%)
Female, n (%) 327 (88%) 15 (94%)
Disease duration in years (m 6 SD) 967.8 5.768.2
ECLAM score (m 6 SD){ 1.661.8 4.663
ECLAM score at end of follow up (m 6 SD) NA 0.460.7
SLEDAI score (m 6 SD){ 3.665.5 18.169.9
SLEDAI score at end of follow up (m 6 SD) NA 0.961.4
SDI score at CNS Onset (m 6 SD) NA 1.460.8
SDI score at end of follow up (m 6 SD) NA 2.161.2
Secondary APS, n (%) 47 (13%) 4 (25%)
Individual Disease Manifestations**
Serositis, n (%) 96 (26%) 6 (38%)
Pleurisy, n (%) 41 (11%) 5 (31%)
Pericarditis, n (%) 40 (11%) 5 (31%)
Arthritis, n (%) 174 (47%) 16 (100%)
Glomerulonephritis, n (%) 164 (44%) 7 (44%)
Class I, n (%) 5 (1.4%) 0 (0%)
Class II, n (%) 42 (11%) 2 (13%)
Class III, n (%) 63 (17%) 2 (13%)
Class IV, n (%) 37 (10%) 1 (6.3%)
Class V, n (%) 42 (11%) 3 (19%)
Class VI, n (%) 4 (1.1%) 0 (0%)
CNS involvement, n (%) 16 (4.3%) 16 (100%)
Hematologic disorder, n (%) 368 (66%) 10 (63%)
Serological Manifestations**
ANA, n (%) 361(96%) 15 (94%)
Anti-dsDNA antibodies, n (%) 345 (70%) 11 (69%)
acL antibodies, n (%) 314 (40%) 8 (50%)
Anti-Rib P antibodies, n (%) Not determined 2 (13%)
NMO-IgG antibodies, n (%) Not determined 2 (13%)
Neurological Manifestations**
Epileptic Seizures, n (%) 6 (1.6%) 6 (38%)
Strokes, n (%) 5 (1.4%) 5 (31%)
Myelopathy, n (%) 4 (1.1%) 4 (25%)
Optic Neuritis, n (%) 1 (0.3%) 1 (6.3%)
Psychosis, n (%) 1 (0.3%) 1 (6.3%)
Aseptic Meningitis, n (%) 1 (0.3%) 1 (6.3%)
1st CNS episode at SLE diagnosis, n (%) NA 7 (44%)
Patients with relapsing CNS episodes, n (%) NA 4 (25%)
Patients with .1 simultaneous CNS events, n (%) NA 2 (13%)
Disease Manifestations Concurrent to CNS Onset
Serositis, n (%) NA 3 (19%)
Arthritis, n (%) NA 16 (100%)
Glomerulonephritis, n (%) NA 5 (31%)
Hematologic disorder, n (%) NA 10 (63%)
Medications**
Corticosteroids, n (%) 339 (92%) 16 (100%)
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Hospitalization Rates
Eighty-seven out of the 370 SLE patients were admitted to the
hospital 141 times during the 3-year follow-up period. 29 patients
were hospitalized more than once. The most common hospital-
ization cause was a lupus flare (59%), while the second more
frequent cause was an infection (20%). No CNS infections
occurred. Flares included glomerulonephritis (27%), cytopenias
(15%), CNS involvement (13%), musculoskeletal symptoms
(8.5%), serositis (5.7%), hepatosplenomegaly and lymph node
enlargement (4.3%), pneumonitis (3.5%), pancreatitis, colitis and
myocarditis (,1%). Nearly one third (33%) of disease flares
presented with more than one overlapping SLE manifestations.
Overall, 16 SLE patients were admitted 18 times for neurological
manifestations (Table 2).
Clinical Associations
We evaluated clinical and serological associations with specific
neurological manifestations for the 16 SLE patients with CNS
involvement. Epileptic seizures were associated with high ECLAM
disease activity score (P = 0.02), late onset during the disease
course (P = 0.03), previous history of serositis (P,0.01), and
glomerulonephritis (P= 0.03). Glomerulonephritis also tended to
occur concurrently to the CNS events (P = 0.03), though no
correlations with any specific types of glomerulonephritis were
found (all P-values .0.10). Further, two clinical associations were of
interest; epileptic seizures tended to associate with high SLEDAI
score (P = 0.07) and younger age at disease onset (P = 0.08).
Myelopathy correlated with lower disease activity scores, low
complement and NMO-IgG antibodies (all P-values ,0.05). Two
patients with myelitis (2/4, 50%) were NMO-IgG/anti-AQP4
positive; the first had Neuromyelitis Optica (NMO) [30], while the
other had Longitudinal Extensive Transverse Myelitis (LETM),
which belongs to the NMO spectrum of disorders [31]. Presence of
strokes tended to associate with secondary APS (P= 0.06) and was
associated with higher SDI scores (P = 0.03). One patient with
acute psychosis was positive only for anti-ribosomal P antibodies
(Figure 1).
Analysis was repeated after removing neurological variables
from ECLAM, SLEDAI and SDI scores. All associations
previously observed with ECLAM remained significant (P,0.05)
after modification (m-ECLAM). The m-SLEDAI score tended to
inversely correlate with myelitis (P= 0.08) but did not correlate
with epileptic seizures (P = 0.23). m-SDI did not correlate with
strokes (P = 0.21).
Table 1. Cont.
Patient Characteristics All SLE patients (n=370)
Patients with CNS Involvement
(n =16)
Azathioprine, n (%) 131 (35%) 4 (25%)
Hydroxychloroquine, n (%) 231 (62%) 7 (44%)
Methotrexate, n (%) 64 (17%) 2 (13%)
Cyclophosphamide, n (%) 123 (33%) 11 (69%)
Mycophenolate Mofetil, n (%) 119 (32%) 8 (50%)
Rituximab, n (%) 35 (9.5%) 5 (31%)
doi:10.1371/journal.pone.0055843.t001
Table 2. Hospitalization causes of SLE patients during the 3 year follow up period.
Cause of Hospitalization Hospitalizations (n) Percentage (%)
Relapse** 83 59%
Glomerulonephritis 38 27%
Hematological 21 15%
CNS 18 13%
Musculosceletal 12 8.5%
Serositis 8 5.7%
Hepatosplenomegaly & Lymph Node Enlargement 6 4.3%
Pneumonitis 5 3.5%
Pancreatitis 3 ,1%
Colitis 3 ,1%
Myocarditis 1 ,1%
Infection 28 20%
Other 30 21%
(Chronic Renal Insufficiency, Cancer, Budd-Chiari Syndrome, alveolar hemorrhage, pulmonary hypertension) (All less than 1%)
Total 141 100%
**Relapse manifestations can coexist during the same hospitalization.
doi:10.1371/journal.pone.0055843.t002
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The 16 patients with CNS involvement were compared to the
remaining 354 SLE patients without neurologic manifestations.
The results from univariate analyses calculating the association of
demographic and clinical characteristics with CNS involvement
are presented in Table 3. Since residual confounding may exist,
multiple logistic regression analysis was used to calculate the
association of ECLAM and SLEDAI scores, modified ECLAM
and SLEDAI scores, aCL antibodies, secondary APS, arthritis,
serositis and glomerulonephritis coexistence with CNS involve-
ment, after adjusting for age, sex, and disease duration. ECLAM
and SLEDAI scores were mutually replaced in the model due to
high inter-correlation. The same mutual replacement was
conducted regarding m-ECLAM and m-SLEDAI, as well as
APS coexistence and aCL antibodies. Arthritis and glomerulone-
phritis were excluded from the SLEDAI models, due to high inter-
correlation. Both unmodified and modified ECLAM and SLEDAI
scores were positively associated with increased likelihood of CNS
involvement (Odds ratio per 1 unit increase in ECLAM= 2.077,
95%CI 1.55–2.79, Odds ratio per 1 unit increase in SLEDAI= 1.39,
95%CI 1.24–1.56, Odds ratio per 1 unit increase in m-ECLAM= 1.56,
95%CI 1.19–2.05, Odds ratio per 1 unit increase in m-SLEDAI= 1.26,
95%CI 1.16–1.41), after adjusting for APS coexistence and the
other factors mentioned above. Similar results were revealed when
aCL antibodies replaced APS coexistence in the previous models
(data not shown). Moreover, in the models that SLEDAI score was
included, APS coexistence was associated with higher likelihood of
CNS involvement (Odds ratio per 1 unit increase in SLEDAI= 0.16,
95%CI 0.03–0.87, Odds ratio per 1 unit increase in m-SLEDAI= 0.26,
95%CI 0.07–1.04), a finding that was not confirmed in models that
included the ECLAM score instead of SLEDAI.
Discussion
This work was focused on the distinction of major CNS
manifestations in SLE and studied their prevalence and incidence
in a cohort of unselected SLE patients. It was shown, that severe
CNS involvement is rather uncommon with a prevalence of 4.3%
and an incidence rate of 7.8/100 person years. Moreover,
ECLAM and SLEDAI scores and APS coexistence were positively
associated with increased likelihood of CNS involvement. Despite
the limitations of the present work, mainly due to the relatively
small sample size, the aforementioned findings deserve further
Figure 1. Numbers of patients with the respective antibodies within each CNS subgroup. Each column group refers to the respective CNS
subgroup. Each column represents a discrete autoantibody, while Y axes displays the number of patients presenting with the respective
autoantibody.
doi:10.1371/journal.pone.0055843.g001
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attention since they highlight the importance and rarity of major
CNS events that can occur in the context of SLE.
CNS involvement can influence both damage accrual and
mortality in SLE [32,33]. This is mostly attributed to the major
CNS manifestations of the disease, including seizures, myelopathy
and strokes [2,32,34]. Furthermore, neurological involvement
appears to be an independent risk factor for hospitalizations in
SLE [35]. Our study reinforces these conclusions, as 13% (18/141)
of SLE hospitalizations in our cohort were due to major CNS
manifestations. An additional clinical observation is that 2 out of
these 141 hospitalizations were in the Intensive Care Unit (ICU).
Both were due to CNS involvement. The aforementioned findings
underline the necessity for rapid diagnosis and treatment in
patients presenting with major CNS manifestations.
The true incidence and prevalence of severe CNS involvement
in SLE is often overshadowed by the inclusion of minor non-
specific symptoms with no direct pathogenetic correlation with
SLE, such as mild cognitive dysfunction, headache, mild
depression, anxiety and paresthesias with negative electroneur-
omyography [9,13]. In the present prospective study, PNS
symptoms and all the aforementioned minor events [9], were
excluded and stringent criteria to include only CNS manifestations
directly attributed to SLE were applied. Moreover, in a 2004
meta-analysis it was shown that prevalence of all types of
headaches in SLE patents was not different from that of healthy
controls [36], while another study has shown that SLE patients
without neurological manifestations exhibit a decline in attention,
memory, and reasoning [17].
Eight major CNS syndromes namely epileptic seizures, strokes,
myelopathy, psychosis, aseptic meningitis, acute confusional state,
chorea and demyelinating syndrome, were included. Although
optic neuritis is categorized by the ACR [8] within the PNS
syndromes, in our study it was included as a CNS event since it
occurred in the context of Neuromyelitis Optica.
The estimated prevalence of definite CNS involvement in SLE
in our cohort was 4.3%, much lower compared to previous
prospective studies in which minor events and PNS symptoms
were included, where the prevalence ranged from 13% to 46%
[4,9,16].
Unlike prevalence, incidence has not been previously calculated,
although a recent review proposed a cumulative incidence of
approximately 30–40% [10]. In our study, incidence was
calculated among newly diagnosed SLE patients (n = 55) during
the 3-year follow-up period, and was 7.8/100 person years. In
published series, most neurologic events tend to accumulate early
during the disease[4,7,10]. CNS involvement was also an early
event in our cohort, as 44% of our patients manifested their CNS
events simultaneously with disease onset.
Roughly 13% of hospitalizations during the 3-year period were
due to SLE-related CNS manifestations, making them the third
more common lupus associated cause for patient admission.
Evidently, even though rare, severe CNS manifestations account
for a notable percentage of hospital admissions in SLE patients.
A statistically significant correlation was found between high
disease activity and CNS manifestations (P,0.001), in line with
other studies [10,37,38]. This conclusion was reinforced after
evaluating our SLE patients using two different disease activity
scores (ECLAM and SLEDAI) and repeating the analysis with the
exclusion of neurological factors from the scores. Moreover, a
statistically significant correlation was observed between secondary
APS and CNS involvement (P= 0.03). Other studies have also
proposed a correlation between neurological manifestations in
SLE and secondary APS [37,39,40].
In our cohort, two discrete clinical phenotypes were identified.
The first was the diffuse phenotype that included epileptic seizures
and psychosis. The second was focal and included myelopathy and
strokes. The correlation of discrete neurological syndromes with
other clinical and serological features of the disease revealed that
epileptic seizures appeared in patients with higher disease activity
scores (P= 0.02 and P=0.07, for ECLAM and SLEDAI scores
respectively), when compared to other neurological manifestations.
Furthermore, patients with epileptic seizures were younger at
disease onset (P = 0.08), in agreement with previous studies [41],
and expressed the seizures later during the disease (P = 0.03),
Table 3. Demographic and clinical characteristics of n= 370 SLE patients by CNS involvement group.
Variables
SLE patients with CNS
Involvement (n=16)
SLE patients without CNS
Involvement (n=354) P
Age at Disease Onset 30612 32614 0.48
Sex 0.70
Male 1 (6.3%) 42 (12%)
Female 15 (94%) 312 (88%)
Disease Duration (yrs) 5.768.2 9.267.8 0.009
aCL antibodies 8 (50%) 140 (40%) 0.60
Secondary APS{ 4 (25%) 43 (12%) 0.13
ECLAM score 4.663 1.461.5 ,0.01
m-ECLAM score{ 3.362.5 1.461.5 0.01
SLEDAI score 1869.9 3.164.1 ,0.01
m-SLEDAI score{ 1268.1 3.164.1 ,0.01
Arthritis 16 (100%) 170 (48%) 0.07
Glomerulonephritis 7 (44%) 157 (44%) 1.00
Serositis 6 (38%) 90 (25%) 0.38
P-values derived through chi-square test for the comparisons of sex, existence of aCL antibodies, secondary APS, arthritis, glomerulonephritis and serositis, and through
Mann-Whitney U-test for the comparisons of age at disease onset, disease duration, ECLAM, SLEDAI, m-ECLAM and m- SLEDAI scores. {m-ECLAM and m-SLEDAI are the
modified scores after exclusion of the neurological variables {APS, Antiphospholipid Syndrome.
doi:10.1371/journal.pone.0055843.t003
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unlike other studies where seizures appeared near the onset of the
disease [42]. Glomerulonephritis was present more often in these
patients and occurred concurrently to the onset of epileptic
seizures (P = 0.03). This observation is in line with a previous
study, where epileptic seizures were a frequent manifestation in
patients with lupus nephritis [43].
Three out of 6 patients who manifested epileptic seizures had
characteristic features in their MRIs; two had Posterior Reversible
Encephalopathy Syndrome (PRES) [44] and 1 had vasculitic-like
lesions. All 3 patients had common clinical features; very high
disease activity, active glomerulonephritis presenting as nephrotic
syndrome, and symptom amelioration following immunosuppres-
sion and antiepileptic treatment. According to previous reports,
two types of PRES in SLE are thought to exist; ‘‘hypertensive
PRES,’’ being reversible with antihypertensive and anticonvulsive
treatment concomitant with inactive SLE, and PRES requiring
immunosuppressive therapy that could be considered a neurolog-
ical manifestation of active SLE [44]. Finally, as seizures preceded
the onset of the nephrotic syndrome, it is unlikely that they were
due to nephrotic encephalopathy.
Myelopathy correlated with lower disease activity scores and the
presence of NMO-IgG/anti-AQP4 antibodies (P#0.05). Patients
with both myelopathy and NMO-IgG antibodies (2/4) had NMO
spectrum symptoms [31]. The first had Neuromyelitis Optica and
the second had LETM. These entities have been previously found
in the context of systemic diseases [45]. A recent study [46]
described two discrete subtypes of lupus myelitis. The first
appeared with gray matter dysfunction, irreversible paraplegia,
higher SLE activity and a CSF profile resembling that of bacterial
meningitis. The second subtype involved patients with white
matter dysfunction and lower SLE activity, who were more likely
to meet criteria for NMO. In our study, patients fell into the
second myelitis subtype.
Strokes appeared more frequently in patients with secondary
APS (P = 0.06) and a worse SDI (P = 0.03). m-SDI did not
correlate to strokes, leading to the assumption that strokes
themselves could aggravate disease damage.
CNS involvement in SLE is due to multiple mechanisms,
including microvasculopathy, autoantibody-mediated injury or
intrathecal production of cytokines that enhance the blood-brain
barrier permeability, thus allowing leukocytes and antibodies to
enter the CNS [10]. Autoantibodies with strong clinical correla-
tion to neurological disease in SLE are the aPL (observed in our
study in 8/16 patients), the anti-ribosomal P antibodies (2/16
patients), and the NMO-IgG/anti-AQP4 antibodies that appeared
in 2 out of 4 patients with myelopathy [10,31,47].
Conclusions
Our study, despite certain limitations (single center, relatively
short follow-up), focused on severe CNS involvement, attributed
with certainty to SLE. Clinically severe CNS involvement appears
to be relatively rare in SLE patients, correlates with disease activity
and manifests with specific features, according to the respective
CNS syndromes. Our work also highlights the necessity for speedy
recognition and intensive treatment of such major events, due to
their significant impact on SLE damage accrual and mortality.
Multicenter and long-term follow up studies could be helpful to
strengthen our conclusions.
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